ATEA PHARMACEUTICALS, INC.

(AVIR)
  Rapport
Temps Différé Nasdaq  -  22:00 05/08/2022
8.790 USD   +4.02%
10/05Atea Pharmaceuticals, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2022
CI
02/03ATEA PHARMACEUTICALS, INC. : JPMorgan Chase maintient sa recommandation neutre
ZM
01/03ATEA PHARMACEUTICALS, INC. : SVB Leerink n'est pas inspiré par le dossier
ZM
SynthèseCotationsGraphiquesActualitésNotationsAgendaSociétéFinancesConsensusRévisionsDérivésFonds 
SynthèseToute l'actualitéReco analystesAutres languesCommuniquésPublications officiellesActualités du secteur
Actualités dans d'autres langues sur ATEA PHARMACEUTICALS, INC.
01/08Atea Pharmaceuticals to Host Second Quarter 2022 Financial Results Conference Call on A..
11/07Atea Pharmaceuticals Participates in the William Blair Biotech Focus Conference
24/06ATEA PHARMACEUTICALS, INC.(NASDAQGS : AVIR) dropped from Russell Small Cap Comp Growth Ind..
24/06ATEA PHARMACEUTICALS, INC.(NASDAQGS : AVIR) added to Russell Microcap Index
24/06ATEA PHARMACEUTICALS, INC.(NASDAQGS : AVIR) dropped from Russell 2000 Growth Index
24/06ATEA PHARMACEUTICALS, INC.(NASDAQGS : AVIR) dropped from Russell 2000 Growth-Defensive Ind..
24/06ATEA PHARMACEUTICALS, INC.(NASDAQGS : AVIR) added to Russell Microcap Value Index
24/06ATEA PHARMACEUTICALS, INC.(NASDAQGS : AVIR) dropped from Russell 3000 Growth Index
24/06ATEA PHARMACEUTICALS, INC.(NASDAQGS : AVIR) added to Russell 3000E Index
24/06ATEA PHARMACEUTICALS, INC.(NASDAQGS : AVIR) dropped from Russell 3000E Growth Index
24/06ATEA PHARMACEUTICALS, INC.(NASDAQGS : AVIR) added to Russell 3000E Value Index
24/06ATEA PHARMACEUTICALS, INC.(NASDAQGS : AVIR) dropped from Russell 2500 Growth Index
21/06ATEA PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K..
01/06Atea Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference
01/06Small Cap Biotechnology Companies Release Positive Quarterly Results (IPA, AVIR, LQDA, ..
10/05ATEA PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition..
10/05TRANSCRIPT : Atea Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 10, 2022
10/05Atea Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 3..
10/05Atea Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business..
03/05Atea Pharmaceuticals to Host First Quarter 2022 Financial Results Conference Call on Ma..
29/034794 : Characterization of the Toxicity Profile of AT-527 (Bemnifosbuvir), a Novel Guanosi..
29/034793 : Lack of Reproductive and Developmental Toxicity for AT-527 (Bemnifosbuvir), an Oral..
28/03Atea Pharmaceuticals Reports Nonclinical Bemnifosbuvir (AT-527) Toxicology Data at Soci..
28/02ATEA PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition..
28/02ATEA PHARMACEUTICALS : Reports Fourth Quarter and Full Year 2021 Financial Results and Pro..
28/02Atea Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31..
28/02TRANSCRIPT : Atea Pharmaceuticals, Inc., Q4 2021 Earnings Call, Feb 28, 2022
28/02ATEA PHARMACEUTICALS : Fourth Quarter 2021 Financial Results Conference Call Presentation
28/02Atea Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended Decemb..
28/02Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Pr..
22/02Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2021 Financial Results Confer..
10/02Atea Pharmaceuticals Appoints Nancy Gail Berry Agrawal, Ph.D., as Executive Vice Presid..
10/02Atea Pharmaceuticals, Inc. Announces Executive Changes
09/02Atea Pharmaceuticals to Present at 11th Annual SVB Leerink Global Healthcare Conference
02/02Atea Pharmaceuticals Announces Publication of Data Supporting Bemnifosbuvir's (AT-527) ..
02/02Atea Pharmaceuticals, Inc. Announces Publication of Data Supporting Bemnifosbuvir’..
10/01TRANSCRIPT : Atea Pharmaceuticals, Inc. Presents at JPMorgan 40th Annual Healthcare Confer..
10/01ATEA PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (..
07/01Atea Pharmaceuticals Highlights Strategic Priorities for 2022
07/01Atea Pharmaceuticals Highlights Strategic Priorities for 2022
07/01Atea Pharmaceuticals, Inc. Provides an Update on the Company’s Clinical Developmen..
07/01NORTH AMERICAN MORNING BRIEFING : Stock Futures -2-
03/01Atea Pharmaceuticals to Present at 40th Annual J.P. Morgan Healthcare Conference
2021ATEA PHARMACEUTICALS, INC.(NASDAQGS : AVIR) added to S&P Pharmaceuticals Select Industry I..
2021ATEA PHARMACEUTICALS, INC.(NASDAQGS : AVIR) added to NASDAQ Biotechnology Index
2021Atea Pharmaceuticals to Be Added to Nasdaq Biotech Index
2021Atea Pharmaceuticals Added to the Nasdaq Biotechnology Index
2021Atea Pharmaceuticals Introduces New Strategic Clinical Development Program for AT-527 i..
2021Atea Pharmaceuticals Introduces New Strategic Clinical Development Program for AT-527 i..
2021ATEA PHARMACEUTICALS, INC. : Regulation FD Disclosure (form 8-K)
2021Atea Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference
2021Health Care Stocks Manage Modest Gains Wednesday
2021Top Midday Decliners
2021Health Care Stocks Moderately Higher This Afternoon
2021GLOBAL MARKETS LIVE : Tesla, Experian, Roche, Activision, Amazon...
2021Atea Pharma Shares Drop 16% After Collaboration With Roche Terminated
2021Wall Street Set to Open Largely Flat, Stabilizing After Boost From Data, Retail Earning..
2021AKTIEN NEW YORK AUSBLICK : Wenig Bewegung - Unternehmensnachrichten im Fokus
2021Top Premarket Decliners
2021Atea Pharmaceuticals to Terminate Roche Collaboration for Development of COVID-19 Oral ..
2021Roche, Atea Pharmaceuticals Cancel COVID-19 Therapy Development Partnership
2021ATEA PHARMACEUTICALS, INC. : Termination of a Material Definitive Agreement (form 8-K)
2021Roche walks away from Atea partnership to develop COVID-19 pill
2021Atea Pharmaceuticals to Terminate Roche Collaboration for Joint Development of COVID-19..
2021Atea Pharma says deal to develop COVID-19 pill with Roche terminated
2021Atea Pharmaceuticals Provides Update on Strategic Collaboration with Roche
2021Atea Pharmaceuticals, Inc. Provides Update on Strategic Collaboration with Roche
2021ATEA PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition..
2021Atea Pharmaceuticals Provides Clinical and Corporate Update and Reports Third Quarter 2..
2021Atea Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Mont..
2021Atea Pharma Q3 Loss Narrows, Plans to Amend Late-Stage Morningsky Trial Protocol -- Sto..
2021TRANSCRIPT : Atea Pharmaceuticals, Inc., Q3 2021 Earnings Call, Nov 11, 2021
2021Third Quarter 2021 Financial Results Conference Call Presentation
2021Atea Pharmaceuticals Provides Clinical and Corporate Update and Reports Third Quarter 2..
2021Atea Pharmaceuticals Provides Clinical and Corporate Update and Reports Third Quarter 2..
1  2  3  4Suiv.
Prochain événement sur ATEA PHARMACEUTICALS, INC.